Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RIGL vs BCRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Captures Overall Composite Edge (59.9 HOLD vs 42.2 HOLD), While BCRX Leads 4–2 on Growth & Valuation Pillars

RIGL Overall Winner 6-Pillar Tally: RIGL 2 – 4 BCRX Matrix Metrics: RIGL 6 – 4 BCRX

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) captures the overall head-to-head institutional edge over BioCryst Pharmaceuticals Inc (BCRX) on higher Unified Composite conviction (59.9/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning, R&D & Supply-Chain Moat), while BCRX wins 4–2 across the 6-pillar growth and valuation breakdown. RIGL trades at $43.73 (9.3x Forward P/E, 26.3% operating margin) versus BCRX at $7.53 (8.9x Forward P/E, 48.8% operating margin).

  • Growth vs. Quality Trade-Off: RIGL earns the overall head-to-head edge with a stronger Unified Composite Score (59.9/100 HOLD vs. BCRX 42.2/100 HOLD) and 1.05β · 74% Vol risk profile, whereas BCRX leads top-line expansion (+13.1% YoY revenue growth, 9.39x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RIGL vs BCRX
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.73
-1.64% 1D
Market Cap $860.3M
TTM Revenue $288M
Forward P/E 9.3x
Beta / 30D Vol 1.05β · 74% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.6 · SMA20: $47.42 · SMA50: $47.34
BCRX NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap $1.9B
TTM Revenue $962M
Forward P/E 8.9x
Beta / 30D Vol 0.77β · 42% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 24.0 Fund 52.0 Flow 67.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.8%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $7.92 · SMA50: $8.18

6-Pillar Scorecard Institutional Category Breakdown (RIGL 2 – 4 BCRX)

Columns: Metric · RIGL · BCRX
1. Valuation Multiples BCRX
Forward P/E 9.3x 8.9x
Trailing P/E 2.8x 13.0x
PEG Ratio N/M 9.39x
EV / Revenue 2.9x 2.7x
2. Growth & Scale BCRX
Revenue Growth (YoY) +16.5% +13.1%
Earnings Growth (YoY) -55.5% +133.3%
TTM Revenue (USD) $288M $962M
Market Cap $860.3M $1.9B
3. Profitability & Quality BCRX
Gross Margin 70.7% 78.1%
Operating Margin 26.3% 48.8%
Net Profit Margin 106.6% -37.4%
Return on Equity (ROE) 109.2% -1925.4%
4. Balance Sheet & Cash Flow BCRX
Cash Generation (TTM) $19M $366M
Cash Flow Margin 6.7% 38.0%
Net Cash / Leverage $39M Net Cash $687M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RIGL
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 61.2% (4th %ile) 60.0% (12th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat RIGL
OpEx & R&D Intensity 44.4% of Rev ($128M) 29.3% of Rev ($282M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RIGL (6) vs BCRX (4)
Institutional Metric RIGL BCRX Criterion Row Edge
Market Capitalization
Scale
$860.3M $1.9B Larger Scale BCRX
Trailing P/E Ratio
Valuation
2.8x 13.0x Lower Multiple RIGL
Forward P/E Ratio
Valuation
9.3x 8.9x Lower Multiple BCRX
Revenue Growth (YoY)
Growth
+16.5% +13.1% Higher Growth RIGL
Operating Margin (TTM)
Profitability
26.3% 48.8% Higher Margin BCRX
Net Profit Margin
Profitability
106.6% -37.4% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
109.2% -1925.4% Higher ROE RIGL
52-Week Range Position
Momentum
68% ($25–$53) 26% ($6–$11) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.05β · 74% Vol 0.77β · 42% Vol Lower Realized Risk BCRX
Unified Institutional Score
Composite Signal
59.9 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$288M $962M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.7% 78.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.9x EV/Rev 9.39x PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$19M ($39M Net Cash) $366M ($687M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BCRX +1.53 pp
RIGL: -4.87% · BCRX: -3.34%
3M Horizon RIGL +22.62 pp
RIGL: +0.25% · BCRX: -22.37%
6M Horizon RIGL +68.9 pp
RIGL: +52.85% · BCRX: -16.05%
1Y Horizon RIGL +0.52 pp
RIGL: +9.65% · BCRX: +9.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RIGL Revenue BCRX Revenue RIGL Op. Margin BCRX Op. Margin Margin Leader
FY2018 $40M $20M -163.3% -456.2% RIGL
FY2019 $60M $50M -116.5% -203.7% RIGL
FY2020 $110M $20M -26.7% -981.1% RIGL
FY2021 $150M $160M -8.4% -113.1% RIGL
FY2022 $120M $270M -46.2% -54.8% RIGL
FY2023 $120M $330M -17.5% -31.3% RIGL
FY2024 $180M $450M 13.5% -0.6% RIGL
FY2025 $290M $870M 42.6% 39.0% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RIGL CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 61.2%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BCRX BREAKDOWN
92d in phase · OBV DISTRIBUTION
Current IV 60.0%
IV Percentile 12th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BCRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published
BCRX Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.9B market capitalization and 48.8% operating margin.
OpEx & R&D Reinvestment 29.3% of Rev ($282M)
90D Engineering Disclosures 0 Published

Investor FAQ RIGL vs BCRX Key Questions & Quantitative Answers

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) captures the overall head-to-head institutional edge over BioCryst Pharmaceuticals Inc (BCRX) on higher Unified Composite conviction (59.9/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning, R&D & Supply-Chain Moat), while BCRX wins 4–2 across the 6-pillar growth and valuation breakdown. RIGL trades at $43.73 (9.3x Forward P/E, 26.3% operating margin) versus BCRX at $7.53 (8.9x Forward P/E, 48.8% operating margin). Growth vs. Quality Trade-Off: RIGL earns the overall head-to-head edge with a stronger Unified Composite Score (59.9/100 HOLD vs. BCRX 42.2/100 HOLD) and 1.05β · 74% Vol risk profile, whereas BCRX leads top-line expansion (+13.1% YoY revenue growth, 9.39x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BCRX leads the Growth & Scale pillar: RIGL posts +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin), compared with BCRX at +13.1% YoY revenue growth and +133.3% YoY earnings growth on $962M TTM revenue (78.1% gross margin, 48.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RIGL cumulative revenue shifted +625.0% while BCRX shifted +4250.0%. In operating R&D and SG&A reinvestment, RIGL deploys 44.4% of Rev ($128M) (0 90-day corporate R&D disclosures) versus 29.3% of Rev ($282M) (0 disclosures) for BCRX.

BCRX screens cheaper on headline valuation multiples. RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin), whereas BCRX trades at 8.9x Forward P/E, 13.0x Trailing P/E, 9.39x PEG, and 2.7x EV/Revenue (38.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RIGL (109.2% ROE) versus BCRX (-1925.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.05β · 74% Vol realized risk). By comparison, BCRX carries 60.0% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.77β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.